🇺🇸 FDA
Pipeline program

ALN-PNP

ALN-PNP-NASH-2255

Phase 1 small_molecule completed

Quick answer

ALN-PNP for Nonalcoholic Fatty Liver Disease (NAFLD) is a Phase 1 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Nonalcoholic Fatty Liver Disease (NAFLD)
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials